文献速递膀胱癌与上尿路尿路上皮癌

患者来源膀胱癌类器官的综合药物筛选与多组学特征揭示吉西他滨反应的新分子关联

Integrative Drug Screening and Multiomic Characterization of Patient-derived Bladder Cancer Organoids Reveal Novel Molecular Correlates of Gemcitabine Response.
PubMed 文献 · Eur Urol · 2024-08-17

研究前瞻性收集膀胱癌患者肿瘤组织建立短期患者来源类器官(PDO)模型,对65个样本进行6至32种药物/组合的体外筛选及多组学分析;短期PDO能忠实反映肿瘤分子特征并避免长期培养所致的基因表达亚型漂移,整合分析识别出吉西他滨反应的多组学特征等潜在预测生物标志物,其阳性预测价值需未来研究验证。

要点

  • 短期PDO保留肿瘤分子特征及多样细胞类型,避免长期培养的基因表达亚型漂移。
  • 整合药物筛选与多组学数据可识别体外药物反应与基因组改变、基因表达及蛋白表达的关联。
  • 体外药物反应及吉西他滨反应多组学特征的阳性预测价值需未来研究验证。

核心结论

  • 短期PDO培养保留肿瘤组织分子特征,并避免长期培养中出现的基因表达亚型漂移。
  • 整合多组学分析与体外药物筛选数据可识别潜在预测生物标志物,包括一种新的吉西他滨反应特征。
  • 体外药物反应及吉西他滨反应多组学特征的阳性预测价值需未来研究验证。

研究设计与样本

  • 前瞻性收集膀胱癌患者肿瘤材料,建立短期患者来源类器官(PDO)模型。
  • 共从97例患者收集106个肿瘤,其中65个样本产生足够材料完成多组学分子特征分析和6至32种药物/组合的PDO筛选。
  • 在体外三维培养中筛选临床相关药物;利用多组学分析验证PDO模型、确定肿瘤分子特征并识别药物反应潜在生物标志物。
  • 采用Spearman秩相关系数评估配对原发组织与PDO样本间的基因表达(GEX)模式;采用Pearson相关系数和Kruskal-Wallis检验及Dunn事后两两比较检验识别治疗反应的分子关联。

主要发现

  • 短期PDO忠实代表肿瘤分子特征,维持多样细胞类型,并避免长期PDO培养伴随的基因表达亚型漂移。
  • 利用整合方法识别出体外药物反应与基因组改变、基因表达及蛋白表达之间的新关联,包括吉西他滨反应的多组学特征。
  • 体外药物反应及新型多组学吉西他滨反应特征的阳性预测价值需未来研究验证。

局限性

  • 体外药物反应及新型多组学吉西他滨反应特征的阳性预测价值需未来研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVE: Predicting response to therapy for each patient's tumor is critical to improving long-term outcomes for muscle-invasive bladder cancer. This study aims to establish ex vivo bladder cancer patient-derived organoid (PDO) models that are representative of patients' tumors and determine the potential efficacy of standard of care and curated experimental therapies. METHODS: Tumor material was collected prospectively from consented bladder cancer patients to generate short-term PDO models, which were screened against a panel of clinically relevant drugs in ex vivo three-dimensional culture. Multiomic profiling was utilized to validate the PDO models, establish the molecular characteristics of each tumor, and identify potential biomarkers of drug response. Gene expression (GEX) patterns between paired primary tissue and PDO samples were assessed using Spearman's rank correlation coefficients. Molecular correlates of therapy response were identified using Pearson correlation coefficients and Kruskal-Wallis tests with Dunn's post hoc pairwise comparison testing. KEY FINDINGS AND LIMITATIONS: A total of 106 tumors were collected from 97 patients, with 65 samples yielding sufficient material for complete multiomic molecular characterization and PDO screening with six to 32 drugs/combinations. Short-term PDOs faithfully represent the tumor molecular characteristics, maintain diverse cell types, and avoid shifts in GEX-based subtyping that accompany long-term PDO cultures. Utilizing an integrative approach, novel correlations between ex vivo drug responses and genomic alterations, GEX, and protein expression were identified, including a multiomic signature of gemcitabine response. The positive predictive value of ex vivo drug responses and the novel multiomic gemcitabine response signature need to be validated in future studies. CONCLUSIONS AND CLINICAL IMPLICATIONS: Short-term PDO cultures retain the molecular characteristics of tumor tissue and avoid shifts in expression-based subtyping that have plagued long-term cultures. Integration of multiomic profiling and ex vivo drug screening data identifies potential predictive biomarkers, including a novel signature of gemcitabine response. PATIENT SUMMARY: Better models are needed to predict patient response to therapy in bladder cancer. We developed a platform that uses short-term culture to best mimic each patient's tumor and assess potential sensitivity to therapeutics.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Merrill NM, Kaffenberger SD, Bao L, et al. Integrative Drug Screening and Multiomic Characterization of Patient-derived Bladder Cancer Organoids Reveal Novel Molecular Correlates of Gemcitabine Response. Eur Urol. 2024. PMID: 39155193. doi:10.1016/j.eururo.2024.05.026

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。